Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1.

Journal article

Proposals for the use of live attenuated human immunodeficiency virus (HIV) type 1 (HIV-1) as a vaccine candidate in humans have been based on the protection afforded by attenuated simian immunodeficiency virus in the macaque model. Although it is not yet known if this strategy could succeed in humans, a study of the Sydney Blood Bank Cohort (SBBC), infected with an attenuated HIV-1 quasispecies with natural nef and nef/long terminal repeat deletions for up to 17 years, could provide insights...

Expand abstract

Authors: Dyer, W; Ogg, G; Demoitie, M; Jin, X; Geczy, A

• Publication status: Published
• Publisher: American Society for Microbiology
• Journal: Journal of virology
• Volume: 73
• Issue: 1
• Pages: 436-443
• Publication date: 1999-01-01
• EISSN: 1098-5514
• ISSN: 0022-538X
• Language: English
• Keywords: nef Gene Products, Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome; Gene Products, nef; Viremia; Humans; HIV-1; Female; Male; Simian immunodeficiency virus; Blood Donors; HLA-A2 Antigen; T-Lymphocytes, Cytotoxic